This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

JOHN W. STEPHENS, M.D.; ROBERT M. DONALDSON, Jr., B.S.; ALEXANDER MARBLE, M.D.

AMA Arch Intern Med. 1951;88(3):356-361.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

WITH THE release of NPH insulin for sale on the open market, details concerning its action become of importance to physicians and patients. This new modified protamine insulin is an "intermediate insulin," with a duration of action longer than that of unmodified (crystalline or regular) but shorter than that of protamine zinc insulin.¹ NPH insulin, however, resembles protamine zinc insulin in its action much more closely than it does unmodified insulin.

The effect of NPH insulin lasts 26 to 30 hr. in the average nonfasting diabetic patient, and the intensity of action is greater than that of protamine zinc insulin at any given time. Thus, patients who previously required an injection of crystalline² insulin along with that of protamine zinc insulin may now, in certain instances, achieve comparable control of diabetes with a single injection of the NPH variety. In certain less easily controlled patients taking NPH insulin, . . . [Full Text PDF of this Article]

Author Affiliations
BOSTON

From the George F. Baker Clinic, Elliott P. Joslin, M.D., Medical Director, New England Deaconess Hospital.

Footnotes
The expenses of this study were borne in part by The Diabetic Fund. NPH insulin was furnished by Eli Lilly & Company, Indianapolis 6.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?